Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis
This real-world, claims-based analysis demonstrates that fumarates and S1P receptor modulators have similar effectiveness in reducing relapses among Black PwMS, with > 72% of patients in both treatment groups remaining relapse-free at 24 months. Given the underrepresentation of Black patients in MS clinical trials, these results provide valuable real-world evidence to guide treatment decisions for this population.
Authors
- Sophia Woodson
- Sylvia Klineova (ORCID: https://orcid.org/0000-0002-0406-0460)
- Jason P. Mendoza (ORCID: https://orcid.org/0000-0003-2526-5542)
- Nicholas Belviso
- Sai L. Shankar (ORCID: https://orcid.org/0000-0003-3249-8360)
- Chu‐Yueh Guo (ORCID: https://orcid.org/0000-0002-5730-7770)
- Kinyee Fong
- James B. Lewin (ORCID: https://orcid.org/0000-0002-2352-9113)
- Rebecca Romero (ORCID: https://orcid.org/0000-0002-1576-5597)
- Jong‐Mi Lee (ORCID: https://orcid.org/0000-0003-2890-5285)
- Boyang Bian (ORCID: https://orcid.org/0000-0003-0153-4218)
- Edward Gettings
- Aljoeson Walker
Institutions
- Biogen (United States) (US)
- Medical University of South Carolina (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of California, San Francisco (US)
- University Hospitals of Cleveland (US)
- Mount Sinai Medical Center (US)
- Stanford Medicine (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1007/s40120-025-00774-2
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen